ArticleUrologie (Heidelberg, Germany)2025
[PSA in the extreme range-an expression of an unfavorable prognosis? : A review of course and treatment of prostate cancer with prostate-specific antigen (PSA) values in the three-to-four-digit range].
Article in Urologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtremely high baseline prostate-specific antigen (bPSA) values in the range of 100 to ≥ 1000 ng/ml prior to the start of systemic therapy pose a challenge, as they can lead to the impression of a very unfavorable prognosis.
objectiveWe investigated factors influencing 5‑year overall survival (5-yOS) and the treatment modalities of patients with bPSA levels ≥ 100 ng/ml using retrospective data. MATERIALS AND
methodsWe defined items from a limited initial collective, which we then used for a query in the UroCloud database. A total of 695 patients were included. RESULTS AND
conclusionFor the entire collective, the 5‑yOS was 68.5% ± 2.7%. The bPSA value had a significant (p < 0.001) influence on 5‑yOS in the following groups: 100-149 ng/ml, 150-249 ng/ml, 250-649 ng/ml, and ≥ 650 ng/ml (5-yOS: 77.0% ± 4.9% vs. 76.9% ± 4.5% vs. 61.4% ± 6.0 vs. 57.4% ± 6.1%, respectively). Age ≤ 70 years compared to > 70 years at first diagnosis resulted in a significant difference regarding 5‑yOS (74.8% ± 3.5% vs. 60.1% ± 4.4, respectively). A PSA response of > 90%, which was achieved in 79.0% of cases, had a significant influence on 5‑yOS compared to a response of ≤ 90% (73.5% ± 2.9% vs. 48.6% ± 6.7%, respectively). There was also a significant 5‑yOS advantage if a first PSA nadir of ≤ 0.20 ng/ml was achieved (in 22.2%) compared to a first PSA nadir of > 0.20 ng/ml (89.8% ± 3.3% vs. 60.4% ± 3.5%, respectively). In 49.4% (n = 343) of cases, androgen deprivation therapy (ADT) monotherapy was started as first-line systemic therapy. Between 1999 and 2023, we saw an increase in escalated and initial combination therapies. The analysis shows that an extreme bPSA value is not in itself an expression of an unfavorable prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.